Literature DB >> 25754914

Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.

Vincenzo Marotta1, Annamaria Colao2, Antongiulio Faggiano2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25754914     DOI： 10.1007/s12020-015-0570-5

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  6 in total

1.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Authors:  Michael R Mancuso; Rachel Davis; Scott M Norberg; Shaun O'Brien; Barbara Sennino; Tsutomu Nakahara; Virginia J Yao; Tetsuichiro Inai; Peter Brooks; Bruce Freimark; David R Shalinsky; Dana D Hu-Lowe; Donald M McDonald
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

2.  The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.

Authors:  Anna Guerra; Maria Rosaria Sapio; Vincenzo Marotta; Elisabetta Campanile; Stefania Rossi; Irene Forno; Laura Fugazzola; Alfredo Budillon; Tania Moccia; Gianfranco Fenzi; Mario Vitale
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

3.  BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma.

Authors:  Vincenzo Marotta; Maria Rosaria Sapio; Anna Guerra; Mario Vitale
Journal:  Expert Opin Med Diagn       Date:  2011-04-21

Review 4.  Targeted therapy with kinase inhibitors in aggressive endocrine tumors.

Authors:  Vincenzo Marotta; Maria Domenica Franzese; Michela Del Prete; Maria Grazia Chiofalo; Valeria Ramundo; Raffaella Esposito; Francesca Marciello; Luciano Pezzullo; Annachiara Carratù; Mario Vitale; Annamaria Colao; Antongiulio Faggiano
Journal:  Expert Opin Pharmacother       Date:  2013-06       Impact factor: 3.889

5.  Sorafenib rechallenge in patients with metastatic renal cell carcinoma.

Authors:  Masahiro Nozawa; Yutaka Yamamoto; Takafumi Minami; Nobutaka Shimizu; Yuji Hatanaka; Hidenori Tsuji; Hirotsugu Uemura
Journal:  BJU Int       Date:  2012-02-14       Impact factor: 5.588

Review 6.  The evolving field of kinase inhibitors in thyroid cancer.

Authors:  V Marotta; C Sciammarella; M Vitale; A Colao; A Faggiano
Journal:  Crit Rev Oncol Hematol       Date:  2014-09-16       Impact factor: 6.312
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.